Commentary: Global Access to Effective Coronavirus Treatments Is Important as the Vaccine

While the science community researches the newly discovered Omicron variant of Covid-19, treatments will become even more necessary where breakthrough cases are detected and those who choose to be unvaccinated are infected. What we already know from the Covid-19 variants is that they are not going away leading to the reality that we will be living with this virus for a long, long time. A vaccine focused approach misses the fact that treatments are going to be needed as a backstop.

The facts surrounding the Omicron variant are emerging day-by-day. CNN reported on November 30, 2021, “there is still a lot we don’t know about the Omicron variant, but scientists are racing to determine its severity, transmissibility and whether it evades current vaccines.” The report indicates that 70 countries have imposed travel restrictions from hot zones in Africa and a growing number of countries outside of Africa are reporting cases. Moderna’s CEO, Stéphane Bancel, worries that the new variant may have an impact on vaccine efficacy while Pfizer’s CEO, Albert Bourla, said that the company is working on an updated vaccine if one is needed. The bottom line is that vaccines have proven to be helpful, yet the Covid-19 pandemic must be fought with vaccines and therapeutics.

Read More

Merck Says Its COVID-19 Pill Is Less Effective than Initially Reported

Merck announced Friday that updated data on its experimental COVID-19 pill show the drug is less effective than previously reported, and will now move to test treatment for safety.

Merck said the pill, Molnupiravir, showed a 30% reduction in hospitalization and deaths based on data from roughly 1,400 patients. Figures from an interim study released Oct. 1 showed an approximately 50% efficacy based on data from over 1,400 patients.

Read More